When a struggling NHS trust needs a chief executive at short notice, it rarely advertises for one. It reaches for someone already known to the system, someone who has done the job before and can be trusted not to make things worse while the board works out what it actually wants. This is how Kevin McGee comes to be taking up an interim role at a large provider trust in England, having spent the years since 2023 running healthcare for a British Overseas Territory of some 33,000 people. He left Lancashire Teaching Hospitals NHS Foundation Trust to become Director General for Healthcare at the Gibraltar Health Authority, and he has now come home to steady an institution in difficulty. The move reads, on paper, like an unremarkable reshuffle. It is worth taking seriously instead as a symptom.

Gibraltar's health system, for all its particular pressures, operates at a scale that bears little resemblance to a major English trust with tens of thousands of patient contacts a year and a workforce running into the thousands. That McGee's overseas tenure is being treated as a credible bridge back into frontline NHS leadership tells you something about how thin the pool of available chief executives has become, not about the transferability of Gibraltar's healthcare challenges to Lancashire's or wherever he lands next. NHS trusts in serious difficulty increasingly turn to a small, recirculating group of leaders who have already held the top job somewhere else, sometimes recently, sometimes after a detour abroad or into consultancy. The interim label used to signal a stopgap. It now increasingly signals a system unable to develop or retain enough substantive candidates to fill permanent posts with confidence.

This matters because the leadership question sits directly beneath every other pressure the NHS is grappling with. Waiting lists remain stubbornly elevated in many specialties, financial settlements continue to demand savings that trusts in deficit struggle to find without cutting into clinical capacity, and workforce morale has not meaningfully recovered from the disputes of the past three years. A trust in genuine difficulty needs a chief executive capable of holding relationships with an exhausted workforce, a sceptical regulator and an impatient integrated care board simultaneously, often while implementing a turnaround plan that requires unpopular decisions. Interim appointments can provide competent stewardship, but they rarely provide the sustained authority that turnaround requires. Staff and clinical leaders know an interim postholder may not be there in eighteen months, and that knowledge shapes how much political capital they are willing to spend on the executive's behalf.

The broader implication reaches NHS England's own workforce planning for its most senior tier, an area that has had far less scrutiny than nursing or medical staffing but arguably carries comparable risk. If the system is relying on leaders returning from small overseas health authorities to fill vacancies at major trusts, that is a signal that succession planning within England's own integrated care systems has not produced enough credible internal candidates ready to step up. It also raises a harder question for policymakers about whether the current model of trust governance, with boards accountable to NHS England for turnaround performance but with limited say over the depth of the leadership market they can draw from, is fit for a period in which dozens of trusts remain under some form of enhanced oversight.

None of this diminishes what McGee may achieve in his new post. Overseas experience running a health system, however small, is not nothing, and competent interim leadership is preferable to a vacant chair. But the pattern his appointment fits into deserves more attention than the appointment itself. A health service that must reach across an ocean and back to find leadership for its most troubled institutions is telling its policymakers something plainly, if nobody is yet listening closely enough to hear it.

‍